UPDATE 2-FDA clears Novo Nordisk's diabetes drug to reduce cardiovascular risk


Novo Nordisk said on Friday the U.S. Food and Drug Administration approved an expanded use of its diabetes drug to reduce the risk of cardiovascular events such as heart attack and stroke. This is the first time the FDA has cleared a diabetes drug for reducing heart-related risks in patients with type 2 diabetes, the company said in a statement.



from Biotech News